What is Sun Pharma Advanced Research Company Ltd's market cap?

Sun Pharma Advanced Research Company Ltd (SPARC) has a market capitalization of ₹6,946 Cr.

What sector is SPARC in?

Sun Pharma Advanced Research Company Ltd operates in the Pharmaceuticals — Formulations & API sector.

What is SPARC's return on equity?

Sun Pharma Advanced Research Company Ltd has a return on equity (ROE) of 77.8%.

Loading company...

Analyzing...

Sun Pharma Advanced Research Company Ltd (SPARC) — Analysis, Financials, Intelligence | The Stock Filter

The Organism · Company Intelligence

Sun Pharma Advanced Research Company Ltd

SPARC|BSE: 532872

Pharmaceuticals — Formulations & APIHealthcare & Life Scienceshttps://www.sparc.life/

₹239.00

+₹10.00 (+4.37%)|MCap ₹6,946 Cr

As of 16 Jun 2026 (End of Day)

52W Low ₹108.0052W High ₹577.00

PE 5.0xMedian PE 3.0xPB 108.7x

Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and current

Secular Currents

Theme Connections

Healthcare Access Pharma CDMO

Intelligence Profile

TSF Score

41/100

The Vitals · Company Health

Health Indicators

Shenanigan Score

59Medium

Trust Score

X-Ray

Concerns

No significant concerns identified

Watch

Nothing flagged for monitoring

Strengths

🟢Strong return on equity (77.8%)Business
🟢Efficient capital deployment (ROCE: 142.6%)Business

The Numbers · Key Metrics

PE Ratio

5.0x

ROE

77.8%

Debt/Equity

-1.19x

₹6,944 Cr

The Narrator · StoryTel Intelligence

FY2025Pharmaceuticals — Formulations & APIProduct Sales ModelModel:Revenue = Volume of Drugs Sold × Average Selling Price (Domestic + Export)

Key Insight

“Operates in Pharmaceuticals — Formulations & API.”

The Revenue Story

₹72 Cr revenue.

Total Income₹74 Cr

Revenue₹72 Cr(97.6% of Total Income)

Other Income₹2 Cr(2.4% of Total Income)

The Cost Story

COGS 32.2%, employees 214.0%.

Other Expenses₹218 Cr(52.4%)

Employee₹154 Cr(36.9%)

Cogs₹23 Cr(5.6%)

Depreciation₹12 Cr(3.0%)

Finance Costs₹9 Cr(2.2%)

-3.7%EBITDA Margin

Other Expenses

52.4%

Employee

36.9%

Cogs

5.6%

Depreciation

3.0%

Finance Costs

2.2%

Key Metrics

ROE

77.8%

vs median 10.5%

ROCE

142.6%

vs median 13.8%

Net Margin

-430.7%

vs median 8.7%

EBITDA Margin

-370.6%

vs median 16.0%

Forward View · Management Guidance

GUIDANCEQ3FY26— 2High Impact

“We need significant additional resources and are finalizing funding plan to extend cash flow through FY 'twenty eight, complete in first half of this calendar year.”

FINANCIALQ3FY26— 2High Impact

“Annual fixed cost savings of about $10,000,000 which is super significant relative to $50,000,000 ish annual spend.”

GUIDANCEQ3FY26— 5High Impact

“we expect to have the maximum tolerated dose or the MTD identified by the end of the third quarter of twenty twenty six”

The Context · Where does it sit?

Sector Context

The Canopy · Sector KPIs

Sector KPIs

Pharmaceuticals — Formulations & API

KPI	Company	Sector Median
ROE	77.8%▲	10.5%
ROCE	142.6%▲	13.8%
Net Margin	-430.7%▼	8.7%
EBITDA Margin	-370.6%▼	16.0%

The Market · What is the market saying?

Market Signals

The Antenna · Media Intelligence

Media Signal

Low Impact

The Numbers · Show me the data

Financials

Revenue₹53 Cr

PBT(₹269 Cr)

EPS(₹8.27)

(₹ Cr)	TTM	FY2025	FY2024
Revenue	₹53 Cr -26.0%	₹72 Cr -5.0%	₹76 Cr
Other Income	₹9 Cr +411.2%	₹2 Cr -93.9%	₹29 Cr
Total Income	₹62 Cr -15.3%	₹74 Cr -30.0%	₹105 Cr
COGS	₹24 Cr +4.4%	₹23 Cr -17.8%	₹28 Cr
	₹319 Cr -23.5%	₹416 Cr -15.4%	₹492 Cr
Profit Before Tax	(₹269 Cr) +21.6%	(₹343 Cr) +11.4%	(₹387 Cr)
Exceptional Items	(₹12 Cr)	₹0.00 Cr	₹0.00 Cr
	(₹0.71 Cr) -163.0%	(₹0.27 Cr) ↓ Decline	₹0.38 Cr
Net Profit	(₹268 Cr) +21.8%	(₹343 Cr) +11.5%	(₹387 Cr)
Profit (Owners)	(₹268 Cr) +21.7%	(₹343 Cr) +11.5%	(₹387 Cr)
Other Comprehensive Income	₹0.83 Cr ↑ Recovery	(₹0.19 Cr) ↓ Decline	₹0.20 Cr
EPS	(₹8.27)	(₹10.56)	(₹11.93)
Diluted Shares	₹32 Cr	₹32 Cr	₹32 Cr